These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

439 related items for PubMed ID: 24165478

  • 1. Vortioxetine for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antidepressant - what is the number needed to treat, number needed to harm and likelihood to be helped or harmed?
    Citrome L.
    Int J Clin Pract; 2014 Jan; 68(1):60-82. PubMed ID: 24165478
    [Abstract] [Full Text] [Related]

  • 2. Levomilnacipran for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antidepressant--what is the number needed to treat, number needed to harm and likelihood to be helped or harmed?
    Citrome L.
    Int J Clin Pract; 2013 Nov; 67(11):1089-104. PubMed ID: 24016209
    [Abstract] [Full Text] [Related]

  • 3. Vilazodone for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antidepressant - what is the number needed to treat, number needed to harm and likelihood to be helped or harmed?
    Citrome L.
    Int J Clin Pract; 2012 Apr; 66(4):356-68. PubMed ID: 22284853
    [Abstract] [Full Text] [Related]

  • 4. Brexpiprazole for schizophrenia and as adjunct for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antipsychotic - what is the number needed to treat, number needed to harm and likelihood to be helped or harmed?
    Citrome L.
    Int J Clin Pract; 2015 Sep; 69(9):978-97. PubMed ID: 26250067
    [Abstract] [Full Text] [Related]

  • 5. Lisdexamfetamine for binge eating disorder in adults: a systematic review of the efficacy and safety profile for this newly approved indication - what is the number needed to treat, number needed to harm and likelihood to be helped or harmed?
    Citrome L.
    Int J Clin Pract; 2015 Apr; 69(4):410-21. PubMed ID: 25752762
    [Abstract] [Full Text] [Related]

  • 6. Deutetrabenazine for tardive dyskinesia: A systematic review of the efficacy and safety profile for this newly approved novel medication-What is the number needed to treat, number needed to harm and likelihood to be helped or harmed?
    Citrome L.
    Int J Clin Pract; 2017 Nov; 71(11):. PubMed ID: 29024264
    [Abstract] [Full Text] [Related]

  • 7. A randomized, double-blind trial of 2.5 mg and 5 mg vortioxetine (Lu AA21004) versus placebo for 8 weeks in adults with major depressive disorder.
    Mahableshwarkar AR, Jacobsen PL, Chen Y.
    Curr Med Res Opin; 2013 Mar; 29(3):217-26. PubMed ID: 23252878
    [Abstract] [Full Text] [Related]

  • 8. Suvorexant for insomnia: a systematic review of the efficacy and safety profile for this newly approved hypnotic - what is the number needed to treat, number needed to harm and likelihood to be helped or harmed?
    Citrome L.
    Int J Clin Pract; 2014 Dec; 68(12):1429-41. PubMed ID: 25231363
    [Abstract] [Full Text] [Related]

  • 9. Valbenazine for tardive dyskinesia: A systematic review of the efficacy and safety profile for this newly approved novel medication-What is the number needed to treat, number needed to harm and likelihood to be helped or harmed?
    Citrome L.
    Int J Clin Pract; 2017 Jul; 71(7):. PubMed ID: 28497864
    [Abstract] [Full Text] [Related]

  • 10. Cariprazine for bipolar depression: What is the number needed to treat, number needed to harm and likelihood to be helped or harmed?
    Citrome L.
    Int J Clin Pract; 2019 Oct; 73(10):e13397. PubMed ID: 31355510
    [Abstract] [Full Text] [Related]

  • 11. Lurasidone for schizophrenia: a review of the efficacy and safety profile for this newly approved second-generation antipsychotic.
    Citrome L.
    Int J Clin Pract; 2011 Feb; 65(2):189-210. PubMed ID: 21129135
    [Abstract] [Full Text] [Related]

  • 12. Vortioxetine: a New Treatment for Major Depressive Disorder.
    Connolly KR, Thase ME.
    Expert Opin Pharmacother; 2016 Feb; 17(3):421-31. PubMed ID: 26679430
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Vortioxetine for the treatment of depression.
    Pearce EF, Murphy JA.
    Ann Pharmacother; 2014 Jun; 48(6):758-65. PubMed ID: 24676550
    [Abstract] [Full Text] [Related]

  • 15. The safety and efficacy of vortioxetine for acute treatment of major depressive disorder: a systematic review and meta-analysis.
    Meeker AS, Herink MC, Haxby DG, Hartung DM.
    Syst Rev; 2015 Mar 01; 4():21. PubMed ID: 25874839
    [Abstract] [Full Text] [Related]

  • 16. Asenapine for schizophrenia and bipolar disorder: a review of the efficacy and safety profile for this newly approved sublingually absorbed second-generation antipsychotic.
    Citrome L.
    Int J Clin Pract; 2009 Dec 01; 63(12):1762-84. PubMed ID: 19840150
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.